Navigation Links
Encision Reports Third Fiscal Quarter Results
Date:1/29/2008

BOULDER, Colo., Jan. 29 /PRNewswire-FirstCall/ -- Encision Inc. (Amex: ECI), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its third fiscal quarter ended December 31, 2007.

Net sales for the third quarter of fiscal year 2008, ended December 31, 2007, totaled $3.13 million, representing a 12% increase over net sales of $2.79 million for the prior fiscal year's third quarter. The Company recorded net income of $59 thousand or $.01 per share for the third quarter of fiscal year 2008 compared to a net loss of $49 thousand or $.01 per share for the third quarter of fiscal year 2007. Net loss for the third quarter of fiscal year 2007 included a one-time expense of $73 thousand, or $.01 per share, relating to the costs of obtaining equity capital financing, a project that was subsequently abandoned after the Company obtained a $2 million line of credit facility from SVB Silicon Valley Bank. Gross profit margin for the third quarter of fiscal year 2008 was 65% as compared to 62% for the third quarter of fiscal year 2007. Gross profit margin for the third quarter of fiscal year 2008 included an approximately 1% increase from the third quarter of fiscal year 2007 gross profit margin that was attributed to a decrease in accrued liabilities related to warranty claims and an approximately 1/2% increase in gross profit margin that was attributed to a limited shipment of our internally manufactured scissor inserts.

"Our improvement in net income in the third quarter ended December 31, 2007 was aided by an increase in gross profit margin from our internal scissor insert manufacturing project," said Jack Serino, President & CEO of Encision Inc. "We began transitioning some customers to our lower cost of goods disposable scissor inserts during the past quarter and are starting to see the impact on our bottom line. We expect to be shipping all Encision-made disposable scissor inserts by the middle of our fiscal year that ends March 31, 2009."

Net sales for the first nine months of fiscal year 2008, ended December 31, 2007, totaled $8.88 million, representing an 8% increase over net sales of $8.19 million for the prior fiscal year's first nine months. The Company recorded a net loss of $228 thousand or $.04 per share for the first nine months of fiscal year 2008 compared to net income of $87 thousand or $.01 per share for the first nine months of fiscal year 2007. Gross profit margin for the first nine months of fiscal year 2008 was 63% as compared to 63% for the first nine months of fiscal year 2007.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600,

mmchaffie@encision.com

ENCISION INC.

Condensed Statements of Operations

(Amounts in thousands, except per share information)

(Unaudited) (Unaudited)

Three Months Ended Nine Months Ended

December 31, December 31, December 31, December 31,

2007 2006 2007 2006

Net sales $3,131 $2,787 $8,883 $8,192

Cost of sales 1,103 1,054 3,301 3,055

Gross profit 2,028 1,733 5,582 5,137

Operating expenses 1,961 1,794 5,797 5,089

Operating income

(loss) 67 (61) (215) 48

Other income (expense) (8) 12 (13) 39

Net income (loss) $59 $(49) $(228) $87

Net income

(loss) per share $0.01 $(0.01) $(0.04) $0.01

ENCISION INC.

Condensed Balance Sheets

(Amounts in thousands)

(Unaudited) (Audited)

December 31, March 31,

2007 2007

Cash and cash equivalents $99 $436

Current assets 3,543 3,637

Total assets 4,627 4,388

Current liabilities 1,775 1,464

Shareholders' equity 2,852 2,923

Total liabilities and

shareholders' equity $4,627 $4,388


'/>"/>
SOURCE Encision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. American Stock Exchange Accepts Encisions Plan to Regain Compliance
2. Zimmer Reports Fourth Quarter and 2007 Financial Results
3. Amylin Pharmaceuticals Reports 2007 Financial Results
4. Cystic Fibrosis Foundation reports upward trend for key health outcomes
5. NBTY Reports First Quarter Results
6. Moog Reports 14% Increase in Earnings Per Share
7. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
8. WellPoint Reports Fourth Quarter and Full Year 2007 Results
9. Air Products Reports Q1 EPS Up 16% on Volume Growth and Improved Margins; Raises 2008 Full Year EPS Guidance
10. TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations
11. Health care reform and 2008 elections: New reports examine candidates plans, publics views
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media ... Janet Yellen and company to wait until March 2017 for an interest rate increase, ... Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
Breaking Medicine Technology: